Effectiveness and Tolerability of Eqwilate in Real-life Conditions

Last updated: March 4, 2021
Sponsor: Octapharma
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04106908
WIL-32
  • Ages > 6
  • All Genders

Study Summary

MOdalities of use, effectiveNEss and TOlerability of Eqwilate® a balanced combInatiON of VWF and FVIII in von WillEbrand patients in real-life conditions: the ONE-TO-ONE study

Eligibility Criteria

Inclusion

Inclusion Criteria: The study will involve patients (≥ 6 years of age) from the participating centres treatedwith Eqwilate® (either on-demand, as perioperative prophylaxis, or as prophylaxis) duringthe time inclusion period will be opened. Patients will be of any VWD type, previouslytreated or untreated.

Exclusion

Exclusion Criteria:

  • N/A

Study Design

Total Participants: 47
Study Start date:
November 27, 2019
Estimated Completion Date:
September 30, 2021

Connect with a study center

  • Caen Study Site

    Caen, 14033
    France

    Site Not Available

  • Clamart Study Site

    Clamart, 92141
    France

    Site Not Available

  • Paris Study Site - Lariboisiere

    Paris, 75010
    France

    Site Not Available

  • Paris Study Site - Necker

    Paris, 75015
    France

    Site Not Available

  • Rennes Study Site

    Rennes, 35033
    France

    Active - Recruiting

  • Rouen Study Site

    Rouen, 76031
    France

    Site Not Available

  • Saint Denis Study Site

    Saint-Denis, 97405
    France

    Site Not Available

  • Saint Denis Study Site - Pediatrie

    Saint-Denis, 97405
    France

    Site Not Available

  • Saint-Etienne Study Site

    Saint-Étienne, 42055
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.